MoneyThe story, in brief
Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma
$400M. That's what Chai Discovery just raised—and it signals Big Pharma is finally betting serious capital on AI-designed drugs.
The KeyNews take
Why it matters
Chai Discovery's $400M Series C (tripling valuation to $3.8B) validates AI-driven drug discovery as a category with real commercial traction. This isn't just a funding win—it's proof that AI models predicting molecular interactions are moving from research labs into pharma production pipelines.
The key facts
6 to know$400M Series C funding raised
Valuation tripled to $3.8 billion
Led by Index Ventures with Kleiner Perkins, Sequoia Capital, Dimension
New investors include Bain Capital
Focus: AI models for predicting biochemical molecule interactions
AI-designed antibodies now reaching Big Pharma deployment
Go to the source
SiliconAnglesiliconangle.com
Publisher excerpt: Chai Discovery Inc., a company that develops artificial intelligence models to predict interactions between biochemical molecules, today announced it has raised $400 million in new funding, nearly tripling its valuation to $3.8 billion. Index Ventures led the Series C round alongside Kleiner…